CN110734978B - Application of DLX1, HOXC6 and PCA3 in preparation of prostate cancer markers and kit thereof - Google Patents
Application of DLX1, HOXC6 and PCA3 in preparation of prostate cancer markers and kit thereof Download PDFInfo
- Publication number
- CN110734978B CN110734978B CN201911102048.2A CN201911102048A CN110734978B CN 110734978 B CN110734978 B CN 110734978B CN 201911102048 A CN201911102048 A CN 201911102048A CN 110734978 B CN110734978 B CN 110734978B
- Authority
- CN
- China
- Prior art keywords
- seq
- pca3
- hoxc6
- dlx1
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses application of DLX1, HOXC6 and PCA3 in preparation of a prostate cancer marker and a kit thereof. The kit uses a multiple qRT-PCR technology to detect DLX1/HOXC6/PCA3 mRNA in a urine sample simultaneously, and simultaneously uses PSA mRNA as a reference to establish a Logistic regression model as a prostate cancer early diagnosis marker. The kit achieves extremely high coincidence rate to the clinical pathological results of the prostate cancer through the joint detection of a plurality of markers.
Description
Technical Field
The invention relates to an application of DLX1, HOXC6 and PCA3 in preparation of a prostate cancer marker and a kit thereof, belonging to the technical field of biological medicine.
Background
Prostate Cancer (PCa) is a malignant tumor which seriously threatens male health, and occupies the second place of the global tumor incidence and the sixth place of mortality, and the incidence of PCa in China increases by 4.7% every year on average, which is the fastest-increasing malignant tumor of men. Data from Shanghai disease control centers show that prostate cancer incidence has been the leading cause of male genitourinary malignancies since 2002.
Prostate specific antigen (Prostate Specific Antigen, PSA) is the most widely used early diagnostic marker for prostate cancer worldwide, and elevated PSA suggests that patients may have prostate cancer, but elevated PSA is often caused by other prostate diseases. Taking the PSA gray area (4-10 ng/ml) as an example, these patients have a positive rate of penetration biopsy of only 10-25%. More than 75% of the daily dearth is counted as prostate needle biopsies, which can cause many complications to the patient, such as hematuria, sepsis, infection, etc., and can cause significant pain to the patient. Although PSA has a wide range of applications, there are also the above-mentioned major problems, and new detection targets are needed to compensate for the defects.
Although the correlation between the expression of some genes in urine and prostate cancer has been found in the prior art, there is still a need in the art to further research related genes which can be practically applied to diagnosis of prostate cancer and develop detection reagents with higher detection accuracy, and prostate cancer may be commonly affected by various gene expressions, so that multiple gene expression detection can be jointly performed for different stages of tumorigenesis and development, and the detection rate of tumors can be obviously improved.
Therefore, it is desirable to provide a kit for the joint detection of a plurality of prostate-associated gene expressions, which can detect a plurality of prostate-cancer-associated gene expressions in a joint manner, and can significantly improve the detection rate of tumors.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides a combined detection kit for the expression of a plurality of prostate-related genes and application thereof, which can detect the expression of the prostate-related genes in a combined way, can obviously improve the detection rate of tumors, has ingenious design and convenient use, and is suitable for large-scale popularization and application.
In order to achieve the above purpose, the invention provides an application of DLX1, HOXC6 and PCA3 in preparing prostate cancer markers and a kit thereof. The kit can detect the expression of the prostate related genes in a combined way, can obviously improve the detection rate of tumors, has ingenious design and convenient use, and is suitable for large-scale popularization and application.
The combined application of DLX1, HOXC6 and PCA3 in the preparation of a prostate cancer marker, wherein the nucleotide sequence of DLX1 is shown as SEQ ID NO.1, the nucleotide sequence of HOXC6 is shown as SEQ ID NO.2, and the nucleotide sequence of PCA3 is shown as SEQ ID NO. 3.
Preferably, the determination formula for the combined application of DLX1, HOXC6 and PCA3 is p=1/[ 1+exp (-z) ], z=1.741×a+0.03×b+0.489×c-4.652, wherein a is a DLX1 score, B is a HOXC6 score, C is a PCA3 score, DLX1 score=dlx1 copy number/PSA copy number; HOXC6 score = HOXC6 copy number/PSA copy number; PCA3 score = PCA3 copy number/PSA copy number.
A kit for jointly detecting prostate cancer by DLX1, HOXC6 and PCA3, which comprises a quantitative detection reagent for DLX1mRNA, HOXC6mRNA and PCA3 mRNA; the DLX1mRNA quantitative detection reagent comprises detection primers shown in SEQ ID NO.9 and SEQ ID NO.10 and a TaqMAN probe with a nucleotide sequence shown in SEQ ID NO. 11; the HOXC6mRNA quantitative detection reagent comprises detection primers shown as SEQ ID NO.12 and SEQ ID NO.13 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 14; the PCA3 mRNA quantitative detection reagent comprises detection primers shown as SEQ ID NO.15 and SEQ ID NO.16 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 17.
Preferably, the kit further comprises a PSA mRNA quantitative detection reagent, wherein the PSA mRNA quantitative detection reagent comprises detection primers shown as SEQ ID NO.18 and SEQ ID NO.19 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 20.
Preferably, the kit also comprises a one-step RT-PCR reaction solution, comprising a SuperScript IV one-step RT-PCR system and Mg 2+ And water.
Preferably, the kit further comprises a standard substance, a negative quality control substance and a positive quality control substance; the standard substance comprises a DLX1 gene recombinant plasmid shown as SEQ ID NO.5, a HOXC6 gene recombinant plasmid shown as SEQ ID NO.6, a PCA3 gene recombinant plasmid shown as SEQ ID NO.7 and a PSA gene recombinant plasmid shown as SEQ ID NO. 8; the positive quality control product is cDNA after reverse transcription of total LNcap RNA of a prostate cancer cell strain, and the negative quality control product is cDNA after reverse transcription of total RWPE-1 RNA of a normal prostate epithelial cell strain.
The invention has the beneficial effects that:
the kit for jointly detecting the expression of the multiple prostate-related genes and the application thereof can jointly detect the expression of the prostate-related genes, can obviously improve the detection rate of tumors, has ingenious design and convenient use, and is suitable for large-scale popularization and application.
Drawings
FIG. 1 is a graph of amplification of a standard sample in the examples;
FIG. 2 is a standard graph in an embodiment;
FIG. 3 is a graph of PCA3 detection ROC;
FIG. 4 is a graph of DLX1+PCA3 detection ROC;
FIG. 5 is a graph of HOXC6+PCA3 detection ROC;
FIG. 6 is a graph of DLX1+HOXC6 detection ROC;
FIG. 7 is a graph of a DLX1+HOXC6+PCA3 joint detection ROC.
Detailed Description
The invention is further described below with reference to the accompanying drawings. The following examples are only for more clearly illustrating the technical aspects of the present invention, and are not intended to limit the scope of the present invention.
A kit for preparing a marker of prostate cancer of DLX1, HOXC6 and PCA3, comprising quantitative detection reagents for DLX1mRNA, HOXC6mRNA and PCA3 mRNA; the DLX1mRNA quantitative detection reagent comprises detection primers shown in SEQ ID NO.9 and SEQ ID NO.10 and a TaqMAN probe with a nucleotide sequence shown in SEQ ID NO. 11; the HOXC6mRNA quantitative detection reagent comprises detection primers shown as SEQ ID NO.12 and SEQ ID NO.13 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 14; the PCA3 mRNA quantitative detection reagent comprises detection primers shown as SEQ ID NO.15 and SEQ ID NO.16 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 17. Because the reaction system of the kit is a quadruple fluorescent RT-PCR reaction system, the probe aiming at each gene is connected with different fluorescent groups. DLX1 probe labeled FAM, HOXC6 probe labeled VIC, PCA3 probe labeled ROX, PSA probe labeled Cy5.
Since PSA is a prostate-specific antigen, PSA gene expression in urine is derived from the prostate, and thus PSA gene (SEQ ID NO. 4) in urine can be used as an internal gene for the amount of prostate-derived RNA. The kit also comprises a PSA mRNA quantitative detection reagent, wherein the PSA mRNA quantitative detection reagent comprises a detection primer shown as SEQ ID NO.18 and SEQ ID NO.19 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 20.
The kit also comprises one-step RT-PCR reaction liquid, and a SuperScript IV one-step RT-PCR system, mg 2+ And water. The kit also comprises a standard substance, a negative quality control substance and a positive quality control substance. The standard substances comprise DLX1 gene recombinant plasmid shown as SEQ ID NO.5, HOXC6 gene recombinant plasmid shown as SEQ ID NO.6, PCA3 gene recombinant plasmid shown as SEQ ID NO.7 and PSA gene recombinant plasmid shown as SEQ ID NO. 8; the yang-property controlling substance is the prostateThe cDNA after reverse transcription of the LNcap total RNA of the adenocarcinoma cell line is the cDNA after reverse transcription of the RWPE-1 total RNA of the normal prostatic epithelial cell line as a negative quality control product.
The invention also provides a method for carrying out the combined detection of the expression of the plurality of prostate-related genes by using the combined detection kit for the expression of the plurality of prostate-related genes, which comprises the following steps: (1) RNA extraction of the sample to be tested using Trizol reagent. (2) And detecting the extracted RNA by using the combined detection kit for the expression of the multiple prostate-related genes to obtain the expression levels of DLX1, HOXC6 and PCA3, thereby evaluating the risk of the prostate cancer.
Example 1:
design and screening of primers and probes
12 groups of forward primers, reverse primers and fluorescent probes are designed according to DLX1, HOXC6, PCA3 and PSA cDNA sequences (SEQ ID NO.1-SEQ ID NO. 4), PCR amplification is carried out by using recombinant plasmids prepared by DLX1, HOXC6, PCA3 and PSA mRNA sequences as templates, sequencing analysis is carried out on amplified products, the reliability of the designed 12 groups of primers and probes is verified, and primers and probes with low amplification efficiency and unspecific amplified products are eliminated. After primary screening, 8 groups of forward primers, reverse primers and fluorescent probes are reserved. And then extracting total RNA of the urine sample, reversely transcribing the total RNA into cDNA, and respectively carrying out PCR amplification by using the 6 groups of forward primers, reverse primers and fluorescent probes after the primary screening, wherein the PCR amplification conditions are as follows: pre-denaturation at 95 ℃ for 3 min; denaturation at 95℃for 10 seconds, annealing/extension at 60℃for 30 seconds, 45 cycles, fluorescence signal detection at the end of extension of each cycle, screening according to the principle of minimum Ct value and maximum fluorescence signal amplification. Through the test process, the forward primer, the reverse primer and the probe sequences (see SEQ ID NO.9-SEQ ID NO. 20) obtained through screening and optimization are obtained.
Example 2, detection System optimization
The purpose is as follows: the concentration of a primer probe (see SEQ ID NO.9-SEQ ID NO. 20) in the reaction system, the selection of an enzyme reaction solution, dNTPs and Mg2+ ion concentration are optimized, so that the PCR reaction system is optimized, and the detection sensitivity and specificity are improved.
1. Primer probe proportional screening
The RT-PCR reactions of four genes are carried out in one reaction tube at the same time, and the PCR effect of other genes is inevitably influenced by each primer probe, so that the concentration of each primer probe is necessary to be screened. We set the amount and ratio of initial primer probes to 0.1uM:0.05uM. The other three primers were kept unchanged at each optimization, and cross-validation was performed sequentially by changing the concentration of only one probe.
The results of the crossover experiments showed that the amounts and ratios of DLX1, HOXC6, PCA3 and PSA primers and probes were 0.3uM, respectively: 0.15uM,0.2uM:0.1uM,0.2uM:0.1uM,0.06uM: a more desirable multiplex amplification effect can be achieved at 0.03. Mu.M.
2. Selection of real-time quantitative PCR reaction premix
For convenient clinical application, the use of one-step RT-PCR reagents is a good choice. The same sample is used for parallel comparison under the same reaction conditions by using a one-step RT-PCR reagent of a plurality of factories for comparing the difference of the fluorescence quantitative reaction premix produced by different factories. The results show that: the SuperScript IV one-step RT-PCR system has the optimal effect, so the SuperScript IV one-step RT-PCR system is selected as a premix for fluorescent quantitative reaction.
3、Mg 2+ Ion concentration optimization
Optimizing the concentration of Mg2+ ions in the system, and adding 0mM,1mM,2mM and 5mM of Mg into the SuperScript IV one-step RT-PCR system 2+ Ions, using the same sample, were compared in parallel under the same reaction conditions. The results show that: 1mM additional Mg was added 2+ The ions have optimal amplification efficiency.
4. dNTP concentration optimization
dNTP concentration in the system is optimized, dNTPs are carried by the SuperScript IV one-step RT-PCR system, 0mM,0.1mM,0.2mM and 0.5mM of dNTPs are additionally added, and parallel comparison is carried out by using the same sample and the same reaction condition. The results show that: the optimal amplification efficiency can be achieved without the addition of dNTPs.
5. Optimization of annealing temperature
According to the Tm value of the primer, the annealing temperature was sequentially increased by 58 ℃, 59 ℃,60 ℃, 61 ℃, 62 ℃, and the annealing temperature was optimized, and the optimal annealing temperature was selected for the subsequent test.
The optimum annealing temperature is preferably 60℃in combination with the efficiency of the PCR amplification reaction and the specificity of the amplification.
6. Optimization of annealing time
And under the condition that the annealing temperature is 60 ℃, the annealing time is respectively set to be 30s, 31s, 32s, 33s and 34s, the annealing time is optimized, and the experimental comparison shows that the finally determined optimal annealing time is 30 seconds.
Example 3 sensitivity experiment
DLX1, HOXC6, PCA3 and PSA cDNA recombinant plasmids were designed according to SEQ ID No.5-SEQ ID No.8 and subjected to gradient dilution respectively, and the concentrations of the recombinant plasmids were 100,000 copies/microliter, 10,000 copies/microliter, 1,000 copies/microliter, 100 copies/microliter, 10 copies/microliter and 1 copy/microliter respectively at 6 dilution points.
PCR detection was performed using the primer probe obtained in example 1 and the reaction conditions in example 2: 95 ℃ for 3 minutes; 95 ℃,10 seconds, 60 ℃,30 seconds, 45 cycles. The amplification curve is shown in FIG. 1, and then a standard curve is drawn according to the detection result, and the result is shown in FIG. 2. The results show that this multiplex fluorescent RT-PCR consisting of DXL1, HOXC6, PCA3 and PSA has very high sensitivity.
Example 4 kit for detection of prostate cancer
Providing a kit comprising: primer probe mixed solution: the primer pair of the 0.3uM DLX1 gene (SEQ ID NO.9, SEQ ID NO. 10), the detection probe of the 0.15uM DLX1 gene (SEQ ID NO. 11), the primer pair of the 0.2uM HOXC6 gene (SEQ ID NO.12, SEQ ID NO. 13), the detection probe of the 0.1uM HOXC6 gene (SEQ ID NO. 14), the primer pair of the 0.2uM PCA3 gene (SEQ ID NO.15, SEQ ID NO. 16), the detection probe of the 0.1uM PCA3 gene (SEQ ID NO. 17), the primer pair of the 0.06uM PSA gene (SEQ ID NO.18, SEQ ID NO. 19), the detection probe of the 0.03uM PSA gene (SEQ ID NO. 20).
PCR reaction solution: superScript IV one-step RT-PCR system, 1mM Mg 2+
Controlling the nature of yang: cDNA after reverse transcription of LNcap total RNA of a prostate cancer cell strain;
negative control: cDNA after reverse transcription of RWPE-1 total RNA of normal prostate epithelial cell strain.
Example 5 clinical sample experiment
206 cases of urine of patients who were about to undergo prostate puncture were collected from urology surgery in a drummer hospital affiliated with the university of south Beijing, and used for implementation. Meanwhile, a standard curve was drawn according to example 4, and the expression amounts of the sample DLX1, HOXC6, PCA3 and PSA genes were absolutely quantified, and a DLX1 score, a HOXC6 score and a PCA3 score were calculated, respectively. Wherein DLX1 score = DLX1 copy number/PSA copy number; HOXC6 score = HOXC6 copy number/PSA copy number; PCA3 score = PCA3 copy number/PSA copy number. The prostate puncture results were used as gold standards (83 cases of prostate cancer and 123 cases of non-prostate cancer in 206 cases of samples), and the Logistic regression model was used to calculate the joint judgment formulas of the genes. In this example, the determination formula for the joint application of DLX1 and HOXC6 is p=1/[ 1+exp (-z) ], z=1.19a+0.137 b-2.192. The judgment formula of the combined application of DLX1 and PCA3 is p=1/[ 1+exp (-z) ], and z=1.783×A+0.527×C-4.694. The combined application of HOXC6 and PCA3 has a judgment formula of p=1/[ 1+exp (-z) ], and z=0.136×b+0.242×c-2.991. The judgment formula of the combined application of DLX1, HOXC6 and PCA3 is p=1/[ 1+exp (-z) ], and z=1.741 x A+0.03 x B+0.489 x C-4.652, wherein A is a DLX1 score, B is a HOXC6 score, C is a PCA3 score, and p values are used for respectively drawing a multi-gene combined detection ROC curve of DLX1+ HOXC6, DLX1+ PCA3, HOXC6+ PCA3 and DLX1+ HOXC6+ PCA 3. The results are shown in fig. 3-7, and the detection performance of the combined detection system is as follows: dlx1+hoxc6+pca3> dlx1+hoxc6> pca3+hoxc6> dlx1+pca3> pca3, AUC values are respectively: 0.8607, 0.7443, 0.7087, 0.7066, 0.6314. According to the ROC curve, when the sensitivity is about 90%, the data of the specificity, the negative predictive value, the positive predictive value and the like of each detection system are compared, and the following table 1 is summarized:
cut-off | AUC | sensitivity of | Specificity (specificity) | NPV | PPV | |
PCA3 scoring | 40 | 0.6314 | 84% | 23% | 87% | 21% |
p-value (DLX 1+ PCA 3) | 0.32 | 0.7066 | 90% | 35% | 89% | 36% |
p-value (PCA3+HOXC6) | 0.24 | 0.7087 | 91% | 38% | 90% | 34% |
p-value (DLX1+HOXC 6) | 0.31 | 0.7443 | 90% | 42% | 90% | 41% |
p-value (DLX1+HOXC6+PCA3) | 0.29 | 0.8607 | 94% | 83% | 93% | 78% |
TABLE 1
The result shows that the sensitivity of the kit for detecting clinical samples can reach 94 percent (78/83), the specificity (102/123) and the total coincidence rate can reach 87 percent, and compared with other molecular markers, the kit has more excellent detection capability and can obviously improve the detection rate of the prostate cancer.
In conclusion, the kit for jointly detecting the expression of the multiple prostate-related genes and the application thereof can jointly detect the expression of the prostate-related genes, can obviously improve the detection rate of tumors, has ingenious design and convenient use, and is suitable for large-scale popularization and application.
The foregoing is merely a preferred embodiment of the present invention, and it should be noted that modifications and variations could be made by those skilled in the art without departing from the technical principles of the present invention, and such modifications and variations should also be regarded as being within the scope of the invention.
Sequence listing
<110> Hangzhou Yiding biotechnology Co Ltd
Application of <120> DLX1, HOXC6 and PCA3 in preparation of prostate cancer markers and kit thereof
<141> 2019-11-12
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2203
<212> DNA
<213> human (homosapiens)
<400> 1
aagctttgaa ccgagtttgg ggagctcagc agcatcatgc ttagactttt caaagagaca 60
aactccattt tcttatgaat ggaaagtgaa aacccctgtt ccgcttaaat tgggttcctt 120
cctgtcctga gaaacataga gacccccaaa agggaagcag aggagagaaa gtcccacacc 180
cagaccccgc gagaagagat gaccatgacc accatgccag aaagtctcaa cagccccgtg 240
tcgggcaagg cggtgtttat ggagtttggg ccgcccaacc agcaaatgtc tccttctccc 300
atgtcccacg ggcactactc catgcactgt ttacactcgg cgggccattc gcagcccgac 360
ggcgcctaca gctcagcctc gtccttctcc cgaccgctgg gctaccccta cgtcaactcg 420
gtcagcagcc acgcatccag cccctacatc agttcggtgc agtcctaccc gggcagcgcc 480
agcctcgccc agagccgcct ggaggaccca ggtcaagatc tggttccaaa acaagcgatc 540
caagttcaag aagctgatga agcagggtgg ggcggctctg gagggtagtg cgttggccaa 600
cggtcgggcc ctgtctgctg gctccccacc cgtgccgccc ggctggaacc ctaactcttc 660
atccgggaag ggctcaggag gaaacgcggg ctcctatatc cccagctaca catcgtggta 720
cccttcagcg caccaagaag ctatgcagca accccaactt atgtgaggtt gcccgcccgt 780
ctccttcttg tctccccggc ccaggtccct cccgcctcca ggtccatcca tcccgtccgg 840
aaaagaagga cccagaggga agaaggaaca gtggaggcgg gacgccctcc atctcctcgg 900
agccccgcga ggtccggccc agcaacttcc cggcatccgc gctctagcct gaaccctggc 960
ctgggccgag cagtggcagc agagagtggc ctcggaggga agccactgcc acctgagaca 1020
gcccaagcag caagataaac ccgctccacc cgacccgccg accttcagct ttgtgggact 1080
atcaggaaaa aacaaaacaa aaacaaaatg tagaaaaagc aaaagctctt ttctgtcctg 1140
tcagtctcct gtctcctttt gctctgtctg tgcgctggta aagtccaggt cctcatccgt 1200
ccgctgtcct cattctgcgg cctcagcaaa aagccacaag gtctgagcgg cccgggtcct 1260
gccgggctga ccatctccgg atcctgggac actctgcctg accatctgtg tagctggtgt 1320
gggaatctgg gggcattgga gggagggggt tttatttatt gagaaatgga cttcgcctga 1380
ggctgtttgc caattcaggg ttctgctggg cgcaaggaac gcactgttca aacgcactgt 1440
ttactttaag cgcacgggga gaaacgaata aggaggacgt ggtgattttt aatttataca 1500
gtaacttttg tacttctctg gtatggagag tttggagccg aatgatttgc attttttaca 1560
tgtccgacat tatttaataa ataattttta aaagaaaaga acgataaatg aagccaacat 1620
gattttctca tttcgggagg aactctgttg cttcgcctgg acaagaagga aaatgctgat 1680
ttcctccttg ggtagaaaga gggagcgagg gcaaatgggg agtagagaga aaacaggcga 1740
gaacaagcac tctaattcca gtgggcttta aaataagaca aaatcagctt tacaacaatc 1800
cctagaggct cgaccacaga ataatgccag tcaccaccct gaacgcacaa tctccagtgc 1860
aggatctaat gactgtacat attattgtta ttattattat tgttattatt gttgttctgt 1920
aaacatgttg cacaagctta gcctttttgc gttctgttgt gtgtggctgt aaaaccccat 1980
gctttgtgaa atgagaatct tgacattttt cttgtgaaat ttggaaaatg tgatcaattg 2040
aaatcaactg tgttttgtgt tctctatgtc aaagtttagt tttatattga gaatgttaac 2100
ttattgcttt gtatcttggg aaaaaaactt tgtaaataag ttataaagtt tctttgagac 2160
agtaaaatta tgatttcttg aaaaaaaaaa aaaaaaaaaa aaa 2203
<210> 2
<211> 1660
<212> DNA
<213> human (homosapiens)
<400> 2
ataaccatct agttccgagt acaaactgga gacagaaata aatattaaag aaatcataga 60
ccgaccaggt aaaggcaaag ggatgaattc ctacttcact aacccttcct tatcctgcca 120
cctcgccggg ggccaggacg tcctccccaa cgtcgccctc aattccaccg cctatgatcc 180
agtgaggcat ttctcgacct atggagcggc cgttgcccag aaccggatct actcgactcc 240
cttttattcg ccacaggaga atgtcgtgtt cagttccagc cgggggccgt atgactatgg 300
atctaattcc ttttaccagg agaaagacat gctctcaaac tgcagacaaa acaccttagg 360
acataacaca cagacctcaa tcgctcagga ttttagttct gagcagggca ggactgcgcc 420
ccaggaccag aaagccagta tccagattta cccctggatg cagcgaatga attcgcacag 480
tggggtcggc tacggagcgg accggaggcg cggccgccag atctactcgc ggtaccagac 540
cctggaactg gagaaggaat ttcacttcaa tcgctaccta acgcggcgcc ggcgcatcga 600
gatcgccaac gcgctttgcc tgaccgagcg acagatcaaa atctggttcc agaaccgccg 660
gatgaagtgg aaaaaagaat ctaatctcac atccactctc tcggggggcg gcggaggggc 720
caccgccgac agcctgggcg gaaaagagga aaagcgggaa gagacagaag aggagaagca 780
gaaagagtga ccaggactgt ccctgccacc cctctctccc tttctccctc gctccccacc 840
aactctcccc taatcacaca ctctgtattt atcactggca caattgatgt gttttgattc 900
cctaaaacaa aattagggag tcaaacgtgg acctgaaagt cagctctgga ccccctccct 960
caccgcacaa ctctctttca ccacgcgcct cctcctcctc gctcccttgc tagctcgttc 1020
tcggcttgtc tacaggccct tttccccgtc caggccttgg gggctcggac cctgaactca 1080
gactctacag attgccctcc aagtgaggac ttggctcccc cactccttcg acgcccccac 1140
ccccgccccc cgtgcagaga gccggctcct gggcctgctg gggcctctgc tccagggcct 1200
cagggcccgg cctggcagcc ggggagggcc ggaggcccaa ggagggcgcg ccttggcccc 1260
acaccaaccc ccagggcctc cccgcagtcc ctgcctagcc cctctgcccc agcaaatgcc 1320
cagcccaggc aaattgtatt taaagaatcc tgggggtcat tatggcattt tacaaactgt 1380
gaccgtttct gtgtgaagat ttttagctgt atttgtggtc tctgtattta tatttatgtt 1440
tagcaccgtc agtgttccta tccaatttca aaaaaggaaa aaaaagaggg aaaattacaa 1500
aaagagagaa aaaaagtgaa tgacgtttgt ttagccagta ggagaaaata aataaataaa 1560
taaatccctt cgtgttaccc tcctgtataa atccaacctc tgggtccgtt ctcgaatatt 1620
taataaaact gatattattt ttaaaacttt aaaaaaaaaa 1660
<210> 3
<211> 3770
<212> DNA
<213> human (homosapiens)
<400> 3
acagaagaaa tagcaagtgc cgagaagctg gcatcagaaa aacagagggg agatttgtgt 60
ggctgcagcc gagggagacc aggaagatct gcatggtggg aaggacctga tgatacagag 120
gtgagaaata agaaaggctg ctgactttac catctgaggc cacacatctg ctgaaatgga 180
gataattaac atcactagaa acagcaagat gacaatataa tgtctaagta gtgacatgtt 240
tttgcacatt tccagcccct ttaaatatcc acacacacag gaagcacaaa aggaagcaca 300
gagatccctg ggagaaatgc ccggccgcca tcttgggtca tcgatgagcc tcgccctgtg 360
cctggtcccg cttgtgaggg aaggacatta gaaaatgaat tgatgtgttc cttaaaggat 420
gggcaggaaa acagatcctg ttgtggatat ttatttgaac gggattacag atttgaaatg 480
aagtcacaaa gtgagcatta ccaatgagag gaaaacagac gagaaaatct tgatggcttc 540
acaagacatg caacaaacaa aatggaatac tgtgatgaca tgaggcagcc aagctgggga 600
ggagataacc acggggcaga gggtcaggat tctggccctg ctgcctaaac tgtgcgttca 660
taaccaaatc atttcatatt tctaaccctc aaaacaaagc tgttgtaata tctgatctct 720
acggttcctt ctgggcccaa cattctccat atatccagcc acactcattt ttaatattta 780
gttcccagat ctgtactgtg acctttctac actgtagaat aacattactc attttgttca 840
aagacccttc gtgttgctgc ctaatatgta gctgactgtt tttcctaagg agtgttctgg 900
cccaggggat ctgtgaacag gctgggaagc atctcaagat ctttccaggg ttatacttac 960
tagcacacag catgatcatt acggagtgaa ttatctaatc aacatcatcc tcagtgtctt 1020
tgcccatact gaaattcatt tcccactttt gtgcccattc tcaagacctc aaaatgtcat 1080
tccattaata tcacaggatt aacttttttt tttaacctgg aagaattcaa tgttacatgc 1140
agctatggga atttaattac atattttgtt ttccagtgca aagatgacta agtcctttat 1200
ccctcccctt tgtttgattt tttttccagt ataaagttaa aatgcttagc cttgtactga 1260
ggctgtatac agccacagcc tctccccatc cctccagcct tatctgtcat caccatcaac 1320
ccctcccatg cacctaaaca aaatctaact tgtaattcct tgaacatgtc aggcatacat 1380
tattccttct gcctgagaag ctcttccttg tctcttaaat ctagaatgat gtaaagtttt 1440
gaataagttg actatcttac ttcatgcaaa gaagggacac atatgagatt catcatcaca 1500
tgagacagca aatactaaaa gtgtaatttg attataagag tttagataaa tatatgaaat 1560
gcaagagcca cagagggaat gtttatgggg cacgtttgta agcctgggat gtgaagcaaa 1620
ggcagggaac ctcatagtat cttatataat atacttcatt tctctatctc tatcacaata 1680
tccaacaagc ttttcacaga attcatgcag tgcaaatccc caaaggtaac ctttatccat 1740
ttcatggtga gtgcgcttta gaattttggc aaatcatact ggtcacttat ctcaactttg 1800
agatgtgttt gtccttgtag ttaattgaaa gaaatagggc actcttgtga gccactttag 1860
ggttcactcc tggcaataaa gaatttacaa agagctactc aggaccagtt gttaagagct 1920
ctgtgtgtgt gtgtgtgtgt gtgagtgtac atgccaaagt gtgcctctct ctctttgacc 1980
cattatttca gacttaaaaa caagcatgtt ttcaaatggc actatgagct gccaatgatg 2040
tatcaccacc atatctcatt attctccagt aaatgtgata ataatgtcat ctgttaacat 2100
aaaaaaagtt tgacttcaca aaagcagctg gaaatggaca accacaatat gcataaatct 2160
aactcctacc atcagctaca cactgcttga catatattgt tagaagcacc tcgcatttgt 2220
gggttctctt aagcaaaata cttgcattag gtctcagctg gggctgtgca tcaggcggtt 2280
tgagaaatat tcaattctca gcagaagcca gaatttgaat tccctcatct tttaggaatc 2340
atttaccagg tttggagagg attcagacag ctcaggtgct ttcactaatg tctctgaact 2400
tctgtccctc tttgtgttca tggatagtcc aataaataat gttatctttg aactgatgct 2460
cataggagag aatataagaa ctctgagtga tatcaacatt agggattcaa agaaatatta 2520
gatttaagct cacactggtc aaaaggaacc aagatacaaa gaactctgag ctgtcatcgt 2580
ccccatctct gtgagccaca accaacagca ggacccaacg catgtctgag atccttaaat 2640
caaggaaacc agtgtcatga gttgaattct cctattatgg atgctagctt ctggccatct 2700
ctggctctcc tcttgacaca tattagcttc tagcctttgc ttccacgact tttatctttt 2760
ctccaacaca tcgcttacca atcctctctc tgctctgttg ctttggactt ccccacaaga 2820
atttcaacga ctctcaagtc ttttcttcca tccccaccac taacctgaat gcctagaccc 2880
ttatttttat taatttccaa tagatgctgc ctatgggcta tattgcttta gatgaacatt 2940
agatatttaa agctcaagag gttcaaaatc caactcatta tcttctcttt ctttcacctc 3000
cctgctcctc tccctatatt actgattgca ctgaacagca tggtccccaa tgtagccatg 3060
caaatgagaa acccagtggc tccttgtggt acatgcatgc aagactgctg aagccagaag 3120
gatgactgat tacgcctcat gggtggaggg gaccactcct gggccttcgt gattgtcagg 3180
agcaagacct gagatgctcc ctgccttcag tgtcctctgc atctcccctt tctaatgaag 3240
atccatagaa tttgctacat ttgagaattc caattaggaa ctcacatgtt ttatctgccc 3300
tatcaatttt ttaaacttgc tgaaaattaa gttttttcaa aatctgtcct tgtaaattac 3360
tttttcttac agtgtcttgg catactatat caactttgat tctttgttac aacttttctt 3420
actcttttat caccaaagtg gcttttattc tctttattat tattattttc ttttactact 3480
atattacgtt gttattattt tgttctctat agtatcaatt tatttgattt agtttcaatt 3540
tatttttatt gctgactttt aaaataagtg attcgggggg tgggagaaca ggggagggag 3600
agcattagga caaataccta atgcatgtgg gacttaaaac ctagatgatg ggttgatagg 3660
tgcagcaaac cactatggca cacgtatacc tgtgtaacaa acctacacat tctgcacatg 3720
tatcccagaa cgtaaagtaa aatttaaaaa aaagtgaaaa aaaaaaaaaa 3770
<210> 4
<211> 1483
<212> DNA
<213> human (homosapiens)
<400> 4
agccccaagc ttaccacctg cacccggaga gctgtgtcac catgtgggtc ccggttgtct 60
tcctcaccct gtccgtgacg tggattggtg ctgcacccct catcctgtct cggattgtgg 120
gaggctggga gtgcgagaag cattcccaac cctggcaggt gcttgtggcc tctcgtggca 180
gggcagtctg cggcggtgtt ctggtgcacc cccagtgggt cctcacagct gcccactgca 240
tcaggaacaa aagcgtgatc ttgctgggtc ggcacagcct gtttcatcct gaagacacag 300
gccaggtatt tcaggtcagc cacagcttcc cacacccgct ctacgatatg agcctcctga 360
agaatcgatt cctcaggcca ggtgatgact ccagccacga cctcatgctg ctccgcctgt 420
cagagcctgc cgagctcacg gatgctgtga aggtcatgga cctgcccacc caggagccag 480
cactggggac cacctgctac gcctcaggct ggggcagcat tgaaccagag gagttcttga 540
ccccaaagaa acttcagtgt gtggacctcc atgttatttc caatgacgtg tgtgcgcaag 600
ttcaccctca gaaggtgacc aagttcatgc tgtgtgctgg acgctggaca gggggcaaaa 660
gcacctgctc gggtgattct gggggcccac ttgtctgtaa tggtgtgctt caaggtatca 720
cgtcatgggg cagtgaacca tgtgccctgc ccgaaaggcc ttccctgtac accaaggtgg 780
tgcattaccg gaagtggatc aaggacacca tcgtggccaa cccctgagca cccctatcaa 840
ccccctattg tagtaaactt ggaaccttgg aaatgaccag gccaagactc aagcctcccc 900
agttctactg acctttgtcc ttaggtgtga ggtccagggt tgctaggaaa agaaatcagc 960
agacacaggt gtagaccaga gtgtttctta aatggtgtaa ttttgtcctc tctgtgtcct 1020
ggggaatact ggccatgcct ggagacatat cactcaattt ctctgaggac acagatagga 1080
tggggtgtct gtgttatttg tggggtacag agatgaaaga ggggtgggat ccacactgag 1140
agagtggaga gtgacatgtg ctggacactg tccatgaagc actgagcaga agctggaggc 1200
acaacgcacc agacactcac agcaaggatg gagctgaaaa cataacccac tctgtcctgg 1260
aggcactggg aagcctagag aaggctgtga gccaaggagg gagggtcttc ctttggcatg 1320
ggatggggat gaagtaagga gagggactgg accccctgga agctgattca ctatgggggg 1380
aggtgtattg aagtcctcca gacaaccctc agatttgatg atttcctagt agaactcaca 1440
gaaataaaga gctgttatac tgtgaaaaaa aaaaaaaaaa aaa 1483
<210> 5
<211> 173
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 5
gagggaagaa ggaacagtgg aggcgggacg ccctccatct cctcggagcc ccgcgaggtc 60
cggcccagca acttcccggc atccgcgctc tagcctgaac cctggcctgg gccgagcagt 120
ggcagcagag agtggcctcg gagggaagcc actgccacct gagacagccc aag 173
<210> 6
<211> 222
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 6
gttccagaac cgccggatga agtggaaaaa agaatctaat ctcacatcca ctctctcggg 60
gggcggcgga ggggccaccg ccgacagcct gggcggaaaa gaggaaaagc gggaagagac 120
agaagaggag aagcagaaag agtgaccagg actgtccctg ccacccctct ctccctttct 180
ccctcgctcc ccaccaactc tcccctaatc acacactctg ta 222
<210> 7
<211> 245
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 7
acaaattact ctggttgctg tgttgatagg acagcagaag ggtaggagca gggacaccag 60
ttaagttatt gcaatggtta aggtgagagg tggtggctgg gcctaggcct ttttggagtg 120
aacaagctat ttgcttggct tccatgatcc ttctccctcc actggaatgg aaggtacttg 180
atattagaga tttttgtctg tttcatcact actgtaaccc caatgtctac aacagactct 240
ggcac 245
<210> 8
<211> 136
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 8
tctgcggcgg tgttctggtg cacccccagt gggtcctcac agctgcccac tgcatcagga 60
acaaaagcgt gatcttgctg ggtcggcaca gcctgtttca tcctgaagac acaggccagg 120
tatttcaggt cagcca 136
<210> 9
<211> 16
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 9
gagggaagaa ggaaca 16
<210> 10
<211> 15
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 10
cttgggctgt ctcag 15
<210> 11
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 11
<210> 12
<211> 14
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 12
gttccagaac cgcc 14
<210> 13
<211> 19
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 13
tacagagtgt gtgattagg 19
<210> 14
<211> 18
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 14
gggccaccgc cgacagcc 18
<210> 15
<211> 17
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 15
acaaattact ctggttg 17
<210> 16
<211> 17
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 16
gtgccagagt ctgttgt 17
<210> 17
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 17
ccatgatcct tctccctcca c 21
<210> 18
<211> 16
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 18
tctgcggcgg tgttct 16
<210> 19
<211> 16
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 19
tggctgacct gaaata 16
<210> 20
<211> 19
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 20
gcccactgca tcaggaaca 19
Claims (5)
- The application of DLX1, HOXC6 and PCA3 quantitative detection reagents in preparing a combined diagnosis kit for prostate cancer is disclosed, wherein the nucleotide sequence of DLX1 is shown as SEQ ID NO.1, the nucleotide sequence of HOXC6 is shown as SEQ ID NO.2, and the nucleotide sequence of PCA3 is shown as SEQ ID NO. 3.
- 2. Use of a quantitative detection reagent for DLX1, HOXC6 and PCA3 according to claim 1 for the preparation of a kit for the combined diagnosis of prostate cancer, characterized in that said kit comprises quantitative detection reagents for DLX1mRNA, HOXC6mRNA and PCA3 mRNA; the DLX1mRNA quantitative detection reagent comprises detection primers shown in SEQ ID NO.9 and SEQ ID NO.10 and a TaqMAN probe with a nucleotide sequence shown in SEQ ID NO. 11; the HOXC6mRNA quantitative detection reagent comprises detection primers shown as SEQ ID NO.12 and SEQ ID NO.13 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 14; the PCA3 mRNA quantitative detection reagent comprises detection primers shown as SEQ ID NO.15 and SEQ ID NO.16 and a TaqMAN probe with a nucleotide sequence shown as SEQ ID NO. 17.
- 3. The use of the quantitative detection reagent of DLX1, HOXC6 and PCA3 according to claim 2 for preparing a kit for combined diagnosis of prostate cancer, wherein the kit further comprises a PSA mRNA quantitative detection reagent comprising a detection primer as shown in SEQ ID No.18 and SEQ ID No.19 and a TaqMAN probe having a nucleotide sequence as shown in SEQ ID No. 20;the judging formula of the combined application of DLX1, HOXC6 and PCA3 is p=1/[ 1+exp (-z) ], and z=1.741 x A+0.03 x B+0.489 x C-4.652, wherein A is a DLX1 score, B is a HOXC6 score, C is a PCA3 score, and DLX1 score=DLX 1 copy number/PSA copy number; HOXC6 score = HOXC6 copy number/PSA copy number; PCA3 score = PCA3 copy number/PSA copy number.
- 4. Use of a quantitative detection reagent for DLX1, HOXC6 and PCA3 according to claim 1 for the preparation of a kit for the combined diagnosis of prostate cancer, characterized in that: the kit also comprises a one-step RT-PCR reaction solution, a SuperScript IV one-step RT-PCR system and Mg 2+ And water.
- 5. Use of a quantitative detection reagent for DLX1, HOXC6 and PCA3 according to claim 1 for the preparation of a kit for the combined diagnosis of prostate cancer, characterized in that: the kit also comprises a standard substance, a negative quality control substance and a positive quality control substance; the standard substance comprises a DLX1 gene recombinant plasmid shown as SEQ ID NO.5, a HOXC6 gene recombinant plasmid shown as SEQ ID NO.6, a PCA3 gene recombinant plasmid shown as SEQ ID NO.7 and a PSA gene recombinant plasmid shown as SEQ ID NO. 8; the positive quality control product is cDNA after reverse transcription of total LNcap RNA of a prostate cancer cell strain, and the negative quality control product is cDNA after reverse transcription of total RWPE-1 RNA of a normal prostate epithelial cell strain.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911102048.2A CN110734978B (en) | 2019-11-12 | 2019-11-12 | Application of DLX1, HOXC6 and PCA3 in preparation of prostate cancer markers and kit thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911102048.2A CN110734978B (en) | 2019-11-12 | 2019-11-12 | Application of DLX1, HOXC6 and PCA3 in preparation of prostate cancer markers and kit thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110734978A CN110734978A (en) | 2020-01-31 |
CN110734978B true CN110734978B (en) | 2023-06-27 |
Family
ID=69272683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911102048.2A Active CN110734978B (en) | 2019-11-12 | 2019-11-12 | Application of DLX1, HOXC6 and PCA3 in preparation of prostate cancer markers and kit thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110734978B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518908B (en) * | 2020-05-18 | 2023-10-17 | 奥尔文泰生物科技(杭州)有限公司 | Urine prostate cancer marker combination and application thereof in preparation of accurate diagnostic reagent |
CN111667918A (en) * | 2020-05-29 | 2020-09-15 | 杭州广科安德生物科技有限公司 | Method for constructing mathematical model for in vitro detection of lung cancer and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110423797A (en) * | 2019-07-11 | 2019-11-08 | 杨海涛 | A kind of primer, method and the kit of the dual real-time PCR of prostate cancer PCA3 gene |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009042742A1 (en) * | 2007-09-25 | 2009-04-02 | The Regents Of The University Of Michigan | Dlx1 cancer markers |
WO2017085553A1 (en) * | 2015-11-20 | 2017-05-26 | Mdxhealth Research B.V. | Method for predicting and treating clinically significant prostate cancer |
US11913076B2 (en) * | 2017-05-12 | 2024-02-27 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Prostate cancer gene profiles and methods of using the same |
-
2019
- 2019-11-12 CN CN201911102048.2A patent/CN110734978B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110423797A (en) * | 2019-07-11 | 2019-11-08 | 杨海涛 | A kind of primer, method and the kit of the dual real-time PCR of prostate cancer PCA3 gene |
Non-Patent Citations (2)
Title |
---|
Urinary biomarkers in prostate cancer detection and monitoring progression;Duojia Wu等;《Critical Reviews in Oncology/Hematology》;20171031;第118卷;摘要、第16页右栏第3段、第23页右栏倒数第1段至第24页左栏第1段 * |
前列腺癌相关生物标志物的研究进展;罗苑方等;《中国医刊》;20190601;第65卷(第06期);第607-610页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110734978A (en) | 2020-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2513780C (en) | Method to detect prostate cancer from a urine sample | |
JP5938690B2 (en) | Abnormal mitochondrial DNA, related fusion transcripts and hybridization probes thereof | |
CN109423515B (en) | Gene markers for liver cancer detection and application thereof | |
CN113604563B (en) | Nucleic acid combination for liver cancer diagnosis or auxiliary diagnosis, detection kit and application thereof | |
CN110628910B (en) | Bladder cancer driving gene point mutation methylation combined auxiliary diagnosis method, kit, system and application | |
CN110734978B (en) | Application of DLX1, HOXC6 and PCA3 in preparation of prostate cancer markers and kit thereof | |
CN110079594B (en) | High-throughput method based on DNA and RNA gene mutation detection | |
CN110541033A (en) | composition for detecting EGFR gene mutation and detection method | |
CN114672568A (en) | Kit for detecting cervical cell gene methylation | |
CN114807350A (en) | Biomarker for judging benign and malignant thyroid nodules, polygene joint inspection kit and application | |
CN117402976A (en) | Rhabdomyosarcoma detection primer probe set, kit and application thereof | |
CN111826446A (en) | Primer, probe and kit for early screening and auxiliary diagnosis of bladder cancer | |
CN113430272B (en) | Reagent and kit for diagnosis or auxiliary diagnosis of esophageal cancer or precancerous lesion and application of reagent and kit | |
CN114277033B (en) | Chinese platycodon root RPL13 reference gene sequence, and primers and application thereof | |
CN112226507B (en) | Papillary thyroid carcinoma serum marker and application | |
CN109355362B (en) | High-sensitivity SNPs detection system and application | |
CN115433778A (en) | Detection reagent and kit for detecting methylation of genes related to colorectal cancer or colorectal adenoma and application of detection reagent and kit | |
US7592137B2 (en) | Genetic testing kits and a method of bladder cancer | |
CN110616264A (en) | Application of DLX1 and HOXC6 in preparation of prostate cancer markers and kit thereof | |
CN113930501A (en) | Digital PCR detection method for human EGFR gene mutation and application | |
KR100858675B1 (en) | Biomarker gene for confirmation of cyst formation | |
CN113005199B (en) | Primer composition for detecting microsatellite instability, kit and application | |
CN113444791B (en) | ARMS-PCR kit for assisting in screening familial papillary thyroid carcinoma | |
CN113957149B (en) | Kit for detecting expression levels of alpha fetoprotein gene and PGR13 gene and application thereof | |
CN109680066B (en) | miRNA for distinguishing left and right half-colon cancers and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |